Literature DB >> 10455325

Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure.

S E Litwin1, S E Katz, J P Morgan, P S Douglas.   

Abstract

1. Chronic treatment with beta-adrenergic blocking agents can improve survival in patients with heart failure. The mechanisms underlying the beneficial effects and whether these effects are generalizable to ischaemic heart failure are unresolved. 2. We performed echocardiographic-Doppler examinations in rats (n=28) 1 and 6 weeks after myocardial infarction (MI) or sham surgery. Rats were randomized to no treatment or propranolol (500 mg/l in drinking water) after the first echocardiogram. Isometric contractions and intracellular Ca transients were recorded simultaneously in noninfarcted left ventricular (LV) papillary muscles. 3. Untreated MI rats had significant LV dilatation (10.6+/-0.4* vs 8.9+/(-0.3) mm, MI vs control), impaired systolic function (fractional shortening=11+/-2* vs 38+/-2%), and a restrictive LV diastolic filling pattern. MI rats receiving propranolol had similar LV chamber sizes (10.6+/(-0.5) mm) and systolic function (13+/(-2%). The propranolol treated animals had higher LV end-diastolic pressures (27+/-2* vs 20+/(-3 mmHg) and a more restricted LV diastolic filling pattern (increased ratio of early to late filling velocities and more rapid E wave deceleration rate). Contractility of papillary muscles from untreated MI rats was depressed (1.6+/(-0.3) vs 2.4+/(0.5 g mm(-2). In addition, Ca transients were prolonged and the inotropic response to isoproterenol was blunted. Propranolol treatment did not improve force development (1.6+/(-0.3 g mm(-2) or the duration of Ca transients during isoproterenol stimulation. 4. Chronic propranolol treatment in rats with postinfarction heart failure did not improve LV remodeling or systolic function. LV diastolic pressures and filling patterns were worsened by propranolol. Treatment also did not produce appreciable improvement in contractility, intracellular Ca regulation or beta-adrenergic responsiveness in the noninfarcted myocardium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455325      PMCID: PMC1566147          DOI: 10.1038/sj.bjp.0702701

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy.

Authors:  B A Bart; L K Shaw; C B McCants; D F Fortin; K L Lee; R M Califf; C M O'Connor
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

2.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials.

Authors:  P A Heidenreich; T T Lee; B M Massie
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

3.  Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction.

Authors:  S E Litwin; S E Katz; J P Morgan; P S Douglas
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

4.  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1997-02-08       Impact factor: 79.321

5.  Heart failure: vive la difference!

Authors:  R P Steeds; K S Channer
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

6.  Contractile function of papillary muscle from rats with different infarct size after beta-adrenergic blockade and ACE-inhibition.

Authors:  K D Wagner; H Theres; A Born; S Strube; N Wunderlich; G Pfitzer; G Baumann; J Günther
Journal:  J Mol Cell Cardiol       Date:  1997-11       Impact factor: 5.000

7.  Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.

Authors:  M Böhm; P Gierschik; K H Jakobs; B Pieske; P Schnabel; M Ungerer; E Erdmann
Journal:  Circulation       Date:  1990-10       Impact factor: 29.690

8.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

Authors:  R N Doughty; G A Whalley; G Gamble; S MacMahon; N Sharpe
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

9.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.

Authors:  E M Gilbert; W T Abraham; S Olsen; B Hattler; M White; P Mealy; P Larrabee; M R Bristow
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  3 in total

1.  Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct.

Authors:  Bing S Huang; Aidong Chen; Monir Ahmad; Hong-Wei Wang; Frans H H Leenen
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

2.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2010

3.  Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery.

Authors:  Zsuzsanna Callaerts-Vegh; Kenda L J Evans; Gregory L Shipley; Peter J A Davies; Donald L Cuba; Hunaid A Gurji; Heather Giles; Richard A Bond
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.